Nutlin-2

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563628

CAS#: 548472-76-0

Description: Nutlin-2 is a potent and selective p53-MDM2 binding inhibitor.

Chemical Structure

img
Nutlin-2
CAS# 548472-76-0
Instruction

Theoretical Analysis

MedKoo Cat#: 563628
Name: Nutlin-2
CAS#: 548472-76-0
Chemical Formula: C31H34Br2N4O4
Exact Mass: 684.09
Molecular Weight: 686.440
Elemental Analysis: C, 54.24; H, 4.99; Br, 23.28; N, 8.16; O, 9.32

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Nutlin-2; Nutlin 2; Nutlin2;

IUPAC/Chemical Name: cis-[4,5-Bis(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-[4-(2-hydroxyethyl)piperazin-1-yl]methanone

InChi Key: PVRYEWOXWGDQHA-WDYNHAJCSA-N

InChi Code: InChI=1S/C31H34Br2N4O4/c1-3-41-27-20-25(40-2)12-13-26(27)30-34-28(21-4-8-23(32)9-5-21)29(22-6-10-24(33)11-7-22)37(30)31(39)36-16-14-35(15-17-36)18-19-38/h4-13,20,28-29,38H,3,14-19H2,1-2H3/t28-,29+/m1/s1

SMILES Code: O=C(N1[C@@H](C2=CC=C(Br)C=C2)[C@@H](C3=CC=C(Br)C=C3)N=C1C4=CC=C(OC)C=C4OCC)N5CCN(CCO)CC5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 686.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhang B, Golding BT, Hardcastle IR. Small-molecule MDM2-p53 inhibitors: recent advances. Future Med Chem. 2015;7(5):631-45. doi: 10.4155/fmc.15.13. Review. PubMed PMID: 25921402.

2: Anil B, Riedinger C, Endicott JA, Noble ME. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallogr D Biol Crystallogr. 2013 Aug;69(Pt 8):1358-66. doi: 10.1107/S0907444913004459. Epub 2013 Jul 13. PubMed PMID: 23897459.

3: ElSawy KM, Verma CS, Joseph TL, Lane DP, Twarock R, Caves LS. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell Cycle. 2013 Feb 1;12(3):394-404. doi: 10.4161/cc.23511. Epub 2013 Jan 16. PubMed PMID: 23324352; PubMed Central PMCID: PMC3587439.

4: Fuller JC, Jackson RM, Edwards TA, Wilson AJ, Shirts MR. Modeling of arylamide helix mimetics in the p53 peptide binding site of hDM2 suggests parallel and anti-parallel conformations are both stable. PLoS One. 2012;7(8):e43253. doi: 10.1371/journal.pone.0043253. Epub 2012 Aug 20. PubMed PMID: 22916232; PubMed Central PMCID: PMC3423354.

5: Rufini A, Melino G. Cell death pathology: the war against cancer. Biochem Biophys Res Commun. 2011 Oct 28;414(3):445-50. doi: 10.1016/j.bbrc.2011.09.110. Epub 2011 Sep 28. Review. PubMed PMID: 21971555.

6: Popowicz GM, Dömling A, Holak TA. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl. 2011 Mar 14;50(12):2680-8. doi: 10.1002/anie.201003863. Epub 2011 Feb 21. Review. PubMed PMID: 21341346; PubMed Central PMCID: PMC3113661.

7: Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle. 2010 Mar 15;9(6):1167-81. Epub 2010 Mar 15. PubMed PMID: 20190571.

8: Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem. 2005 Jul 14;48(14):4491-9. Review. PubMed PMID: 15999986.

9: Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844-8. Epub 2004 Jan 2. PubMed PMID: 14704432.